Probiotic Strains for Gut Repair
The probiotic supplement market is dominated by generic multi-strain formulations marketed for general gut health, but the clinical evidence is not generic — it is strain-specific. The differences between two Lactobacillus rhamnosus strains can be larger than the differences between Lactobacillus and Bifidobacterium. The clinical literature has identified a small number of specific strains with strong evidence for specific indications: Lactobacillus rhamnosus GG (the ATCC 53103 strain isolated by Gorbach and Goldin) for acute and antibiotic-associated diarrhea, Saccharomyces boulardii CNCM I-745 (the only commercial yeast probiotic) for Clostridioides difficile and traveler's diarrhea, a high-dose 8-strain mixture for ulcerative colitis and pouchitis, and Bifidobacterium longum 35624 for IBS. This deep-dive walks through the strain-by-strain evidence base, the practical CFU dosing, the post-antibiotic recolonization window, the contraindications in immunocompromise, and the distinction between probiotic supplements and fermented foods.
Table of Contents
- Why Strain-Specific Evidence Matters
- Lactobacillus rhamnosus GG (LGG)
- Saccharomyces boulardii CNCM I-745
- The High-Dose Eight-Strain Mixture
- Bifidobacterium longum 35624
- Other Strains with Meaningful Evidence
- CFU Dosing and Practical Use
- The Post-Antibiotic Recolonization Window
- Fermented Foods vs Probiotic Supplements
- Cautions and Contraindications
- Key Research Papers
- Connections
- Featured Videos
Why Strain-Specific Evidence Matters
Bacterial taxonomy is hierarchical: genus → species → strain. A bacterial strain is a specific isolate of a species with a characterized genome and phenotype, typically identified by alphanumeric designation (e.g., GG, 35624, NCFM, BB-12). The differences between strains of the same species can be enormous — gene content can vary by 20-30% between strains, and clinical effects vary correspondingly.
The International Scientific Association for Probiotics and Prebiotics (ISAPP) defines probiotics as "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host." The "adequate amounts" and "health benefit" are both strain-specific. A claim like "Lactobacillus acidophilus is good for digestion" is scientifically empty — the meaningful claim is "L. acidophilus NCFM at 10 billion CFU/day reduced bloating in patients with functional dyspepsia in trial X."
Practical implications for selecting a probiotic:
- Read the label for full strain designation (genus + species + alphanumeric strain code, e.g., L. rhamnosus GG, not just "Lactobacillus rhamnosus")
- Match the strain to the indication based on published trials
- Verify the CFU count matches the trial dosing
- Verify the CFU count is guaranteed through expiration (not at manufacture)
- Verify refrigeration requirements (many strains require cold chain; lyophilized strains are more stable)
Lactobacillus rhamnosus GG (LGG)
Lactobacillus rhamnosus GG (also designated ATCC 53103) is the most extensively studied probiotic strain in the world — over 1,000 published trials and observational studies. The strain was isolated in 1985 by Sherwood Gorbach and Barry Goldin at Tufts University (the "GG" stands for Gorbach-Goldin) from the gastrointestinal tract of a healthy human volunteer.
The major LGG indications with strong evidence:
- Acute infectious diarrhea in children — Cochrane meta-analyses consistently show LGG reduces diarrhea duration by approximately 1 day in pediatric acute gastroenteritis
- Antibiotic-associated diarrhea (AAD) — LGG given alongside an antibiotic course reduces AAD risk by ~50% in pediatric and adult populations
- Traveler's diarrhea prevention — modest reduction in incidence with prophylactic LGG (10-20 billion CFU daily) starting 1-2 days before travel
- Atopic dermatitis prevention in infants — reduced eczema incidence at 2-7 years in children whose mothers took LGG during pregnancy and early breastfeeding
- Pediatric IBD adjunct — modest effect in some trials
The dose used in most clinical trials is 10-20 billion CFU per day, typically as one or two divided doses. LGG is acid-stable and bile-stable, surviving stomach passage well. It does not permanently colonize the gut — transit time studies show it disappears from stool within 1-2 weeks of discontinuation. The clinical effect is therefore dependent on continuous administration.
Commercial forms: LGG is sold over the counter as a single-strain product and appears in many multi-strain formulations.
Saccharomyces boulardii CNCM I-745
Saccharomyces boulardii is the only yeast probiotic with rigorous clinical evidence. It was isolated in 1923 by French microbiologist Henri Boulard from lychee fruit in Indochina (now Vietnam), after he observed that the local population brewed a lychee tea to treat cholera-related diarrhea. The CNCM I-745 strain (sold in the US under many product names) is the strain with the published clinical evidence base.
Because S. boulardii is a yeast rather than a bacterium, it is intrinsically resistant to antibacterial antibiotics — making it the ideal probiotic to take alongside an antibiotic course without antibiotic killing the supplement. Its mechanism is multifactorial: it secretes a 54 kDa protease that cleaves Clostridioides difficile toxin A, it stimulates secretory IgA production, it competitively inhibits adhesion of pathogenic bacteria, and it stimulates short-chain fatty acid production by other commensals.
Major indications with strong evidence:
- Clostridioides difficile prevention — in patients receiving high-risk antibiotics (clindamycin, broad-spectrum cephalosporins, fluoroquinolones), S. boulardii reduces C. difficile-associated diarrhea by ~50%
- Antibiotic-associated diarrhea — meta-analyses show ~40-50% reduction in AAD across diverse populations
- Traveler's diarrhea prevention — 250 mg BID starting before travel reduces incidence
- Pediatric acute diarrhea — reduces duration similar to LGG
- Recurrent C. difficile infection — adjunct to vancomycin or fidaxomicin reduces recurrence
- Hepatic encephalopathy — modest evidence for reducing ammonia production by gut flora
Dosing: typical clinical dose is 250-500 mg twice daily (one 250 mg capsule contains approximately 5 billion CFU). For C. difficile prevention alongside antibiotics, start with the first antibiotic dose and continue for 1 week after antibiotic completion.
The High-Dose Eight-Strain Mixture
This high-dose 8-strain mixture contains eight bacterial strains: four Lactobacillus (L. plantarum, L. paracasei, L. acidophilus, L. delbrueckii subsp. bulgaricus), three Bifidobacterium (B. breve, B. longum, B. infantis), and one Streptococcus (S. thermophilus). Total CFU is 450 billion per sachet (the prescription-strength version) or 112.5 billion per capsule (the consumer-grade version).
The history is complicated. The original formulation was developed by Italian gastroenterologist Claudio De Simone. Since 2016 the original De Simone Formulation and a later reformulation have been sold in North America under different product names, and the two are not documented to contain identical strains. The published clinical results below come from the original De Simone Formulation.
Major indications with strong evidence:
- Pouchitis — following ileal pouch-anal anastomosis for ulcerative colitis, pouchitis affects ~50% of patients. Gionchetti's trial showed the eight-strain mixture effective for maintenance of remission after a course of metronidazole, and effective for primary prevention in the first year post-surgery
- Ulcerative colitis induction and maintenance — multiple RCTs (Sood, Tursi, Miele) show added benefit when the eight-strain mixture is combined with standard 5-aminosalicylate therapy. Endoscopic remission rates improved
- Pediatric ulcerative colitis — Miele 2009 RCT showed the eight-strain mixture plus standard induction improved remission rate vs placebo
- IBS — modest effect, less clear than the IBD evidence
- Hepatic encephalopathy — reduces ammonia and improves cognitive function
Dosing: in active ulcerative colitis, the trial dosing is 900 billion CFU per day (2 sachets BID). For maintenance, 450 billion CFU per day. For pouchitis maintenance, 450-900 billion CFU per day. These doses are far higher than typical OTC probiotics, which is part of the clinical efficacy story — the high CFU saturates the colon and produces measurable changes in fecal short-chain fatty acid production.
Bifidobacterium longum 35624
Bifidobacterium longum 35624 is the strain with the strongest IBS evidence in any monostrain formulation. It was developed at the Alimentary Pharmabiotic Centre at University College Cork by Eamonn Quigley and colleagues, originally isolated from a healthy human gastrointestinal tract. The Whorwell et al. 2006 trial published in American Journal of Gastroenterology randomized 362 women with IBS to one of three doses of B. infantis 35624 (later reclassified as B. longum 35624 after taxonomic revision) or placebo for 4 weeks. The 1 billion CFU/day dose produced significant improvement in abdominal pain/discomfort, bloating/distension, and bowel-habit satisfaction compared with placebo.
Subsequent studies have confirmed the effect and identified the likely mechanism: B. longum 35624 reduces pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1) and increases regulatory cytokines (IL-10), shifting the gut immune set-point toward tolerance.
Commercial form: sold over the counter in the US as a single-strain capsule. The labeled dose is 1 billion CFU per capsule, taken once daily. Onset of clinical effect typically requires 4-6 weeks of daily use.
Indications:
- IBS (all subtypes, but particularly IBS-M and IBS-C) — Level 1 evidence from Whorwell
- Postinfectious IBS — reasonable adjunct to glutamine
- Functional bloating — modest evidence from secondary analyses
Other Strains with Meaningful Evidence
- Lactobacillus reuteri DSM 17938 — strongest evidence in infant colic and pediatric functional gastrointestinal disorders. Dose: 100 million CFU/day in infants.
- Lactobacillus plantarum 299v — iron absorption enhancement and IBS abdominal pain reduction. Dose: 20 billion CFU/day.
- Bifidobacterium infantis EVC001 — for breastfed infants. Specifically utilizes human milk oligosaccharides (HMOs). Most effective in cesarean-delivered or antibiotic-exposed infants who lack normal vertical transfer.
- Bifidobacterium animalis subsp. lactis BB-12 — broad evidence base in immune function and gut transit. Often in multi-strain formulations.
- Lactobacillus acidophilus NCFM — oldest commercial strain, modest evidence in lactose digestion and AAD prevention.
- Streptococcus salivarius K12 and M18 — oral cavity probiotics (different niche). K12 for strep throat / tonsillitis recurrence, M18 for dental health.
- Akkermansia muciniphila — mucin-degrading gut commensal under active investigation for metabolic disease and gut barrier. Newer commercial products (Pendulum) just emerging from clinical development.
CFU Dosing and Practical Use
Clinical trial CFU dosing varies enormously by strain and indication:
- Low-dose mono-strain (LGG for general use): 10 billion CFU/day
- Mid-dose mono-strain (B. longum 35624): 1 billion CFU/day
- High-dose mono-strain (S. boulardii for C. diff prevention): 5-10 billion CFU/day
- Multi-strain (typical OTC): 25-100 billion CFU/day
- High-dose multi-strain (the eight-strain mixture for UC): 450-900 billion CFU/day
Practical timing: most probiotics are best taken with food (the buffering effect of food on stomach acid increases survival through stomach passage). Exception: S. boulardii, which is intrinsically acid-stable and can be taken any time. For high-CFU multi-strain formulations, splitting the daily dose into 2-3 administrations may improve colonization saturation.
CFU degradation between manufacture and consumption is the biggest source of OTC probiotic underdosing. Many products are labeled at manufacture CFU; by the time of consumption (after warehouse, shipping, retail storage, home storage), actual CFU may be 10-50% of label. Labels stating "CFU guaranteed through expiration date", with clearly stated refrigeration requirements, are the ones that address this gap.
The Post-Antibiotic Recolonization Window
Antibiotics reduce gut microbial diversity dramatically — broad-spectrum antibiotic courses (clindamycin, cephalosporins, fluoroquinolones) can reduce gut bacterial CFU by 2-3 log within days. Recovery is partial and often incomplete: trials of stool microbiome 6 months after a single antibiotic course typically show persistent loss of approximately 10-20% of the pre-antibiotic species, with the lost organisms not returning even at 1 year follow-up.
The post-antibiotic period is therefore both a window of risk (dysbiosis, C. difficile susceptibility, opportunistic overgrowth) and a window of opportunity (the relatively empty niche may be more receptive to colonization by deliberately introduced strains). Standard recommendations:
- During antibiotic course — S. boulardii 250 mg BID (yeast is unaffected by antibacterial antibiotics). Start with the first antibiotic dose
- During antibiotic course, alongside S. boulardii — LGG 10 billion CFU BID, taken 2-3 hours separated from antibiotic dose to maximize survival
- For 4 weeks after antibiotic completion — continue multi-strain probiotic, add prebiotic fiber (resistant starch, partially hydrolyzed guar gum), increase fermented food intake
- For longer-term recovery — emphasize a diverse plant-rich diet (Mediterranean or anti-inflammatory pattern), regular fermented foods, and avoidance of unnecessary additional antibiotics
An emerging research area is autologous fecal microbiota transplantation — storing one's own stool before a planned antibiotic course (e.g., before elective surgery, chemotherapy) and reinstating it afterward via colonoscopy. Early trial evidence (Taur et al. 2018, Suez et al. 2018) supports this approach for restoring pre-antibiotic microbiome composition, but autologous FMT is not yet commercially available outside research settings.
Fermented Foods vs Probiotic Supplements
Fermented foods (sauerkraut, kimchi, kefir, yogurt, kombucha, miso, natto, tempeh) and probiotic supplements are complementary, not interchangeable.
Probiotic supplements:
- Defined strain identity at known CFU dose
- Clinical trial evidence for specific indications
- Reliable delivery of the strain that was studied
- Generally narrow strain diversity (1-8 strains)
- No food matrix or co-occurring fermentation metabolites
Fermented foods:
- Broad strain diversity (dozens of species in mixed sauerkraut)
- Variable CFU, lacks formal trial CFU dosing
- Includes post-biotic metabolites (organic acids, bacteriocins, B vitamins, enzymes)
- Food matrix provides additional nutrients and fiber
- Higher diversity but less reliable strain identity
- Stanford SCI trial (Wastyk 2021) showed fermented foods reduced 19 inflammatory markers vs a high-fiber diet in healthy adults — one of the strongest signals for fermented food benefit
The two play different roles in the research: daily fermented foods (1-2 servings of properly fermented sauerkraut, kimchi, kefir, or yogurt) for diversity, and targeted probiotic strains matched to a specific indication (LGG for AAD, S. boulardii alongside antibiotics, the eight-strain mixture for UC, B. longum 35624 for IBS, etc.).
Cautions and Contraindications
- Severe immunocompromise — the most consequential warning. Probiotic-associated bacteremia/fungemia has been reported in HIV/AIDS, post-transplant immunosuppression, neutropenia, indwelling central venous catheters, and short-bowel syndrome. Cases of Lactobacillus bacteremia and S. boulardii fungemia, while rare, are well documented. Probiotics should not be routinely used in these populations without specialist input.
- SIBO (small intestinal bacterial overgrowth) — in some SIBO patients, probiotic supplementation worsens symptoms by adding to the bacterial overgrowth in the small intestine. Generally, probiotics in SIBO should follow eradication therapy, not precede it. The exception: spore-based probiotics (Bacillus subtilis, Bacillus coagulans) which transit through the small intestine without colonizing it and may be better tolerated.
- Histamine intolerance — certain Lactobacillus strains (L. casei, L. bulgaricus, L. helveticus) produce histamine and may worsen symptoms in histamine-intolerant patients. Histamine-degrading strains (B. infantis, L. plantarum, L. rhamnosus) are preferred.
- D-lactic acidosis in short-bowel syndrome — in patients with short-bowel syndrome, certain lactobacilli can produce D-lactic acid that accumulates to neurotoxic levels. Probiotic selection in short-bowel patients requires specialist input.
- Allergic reaction to dairy or yeast — some probiotic preparations are grown in dairy or yeast media; check label and avoid in severe allergy.
- PROPATRIA trial cautionary signal — this 2008 trial of probiotic supplementation in severe acute pancreatitis showed increased mortality in the probiotic arm. The trial used a specific high-dose multi-strain formulation in a critically ill population with bowel ischemia; the result has not been replicated in other settings but remains a cautionary tale for high-dose probiotic use in severe systemic illness.
- Heart valve disease, prosthetic heart valves — theoretical concern about probiotic bacteremia and endocarditis; discuss with cardiology before chronic high-dose use.
Key Research Papers
- Szajewska H, Kolodziej M (2015). Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther. — PubMed PMID: 26365389
- McFarland LV (2010). Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. — PubMed PMID: 20458757
- Gionchetti P et al. (2000). Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. — PubMed PMID: 10930365
- Tursi A et al. (2010). Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment. Am J Gastroenterol. — PubMed
- Whorwell PJ et al. (2006). Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. — PubMed PMID: 16863564
- Goldenberg JZ et al. (2017). Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database. — PubMed PMID: 29257353
- Hill C et al. (2014). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. — PubMed
- Suez J et al. (2018). Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell. — PubMed PMID: 30193113
- Wastyk HC et al. (2021). Gut-microbiota-targeted diets modulate human immune status. Cell. — PubMed PMID: 34256014
- Besselink MG et al. (2008). Probiotic prophylaxis in predicted severe acute pancreatitis: PROPATRIA. Lancet. — PubMed
- Doron S, Snydman DR (2015). Risk and safety of probiotics. Clin Infect Dis. — PubMed
- Miele E et al. (2009). Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. — PubMed